key: cord-0816016-y1ca2hk8
authors: Lipworth, S.; Rigby, I.; Cheng, V.; Bannister, P.; Harriss, E.; Cook, K.; Cai, E.; Tattan, M.; Epie, T.; Manoharan, L.; Lambe, K.; Michelen, M.; Gilibets, A.; Dagens, A.; Sigfrid, L.; Horby, P.
title: From SARS and MERS to COVID-19: a review of the quality and responsiveness of clinical management guidelines in outbreak settings
date: 2021-01-15
journal: nan
DOI: 10.1101/2021.01.12.21249654
sha: 6fbf4415a2252e374464ae5a639c739c0cb4c3c6
doc_id: 816016
cord_uid: y1ca2hk8

Objective: To assess the responsiveness and quality of clinical management guidelines (CMGs) in SARS, MERS and COVID-19 and determine whether this has improved over time. Design: Rapid literature review, quality assessment and focus group consultation. Data Sources: Google and Google scholar were systematically searched from inception to 6th June 2020.This was supplemented with hand searches of national and international public health agency and infectious disease society websites as well as directly approaching clinical networks in regions where few CMGs had been identified via the primary search. Eligibility Criteria- CMGs for the treatment of COVID-19/SARS/MERS providing recommendations on supportive care and/or specific treatment. Methods: Data extraction was performed using a standardised form. The Appraisal of Guidelines for Research and Evaluation (AGREE-II) tool was used to evaluate the quality of the CMGs. Six COVID-19 treatments were selected to assess the responsiveness of a subset of guidelines and their updates to 20th November 2020. We ran two sessions of focus groups with patient advocates to elicit their views on guideline development. Results: We included 37 COVID-19, six SARS, and four MERS CMGs. Evidence appraisals in CMGs generally focused on novel drugs rather than basic supportive care; where evidence for the latter was provided it was generally of a low quality. Most CMGs had major methodological flaws (only two MERS-CoV and four COVID-19 CMGs were recommended for use by both reviewers without modification) and there was no evidence of improvement in quality over time. CMGs scored lowest in the following AGREE-II domains: scope and purpose, editorial independence, stakeholder engagement, and rigor of development. Of the COVID-19 CMGs, only eight included specific guidance for the management of elderly patients and only ten for high-risk groups; a further eight did not specify the target patient group at all. Early in the pandemic, multiple guidelines recommended unproven treatments and whilst in general findings of major clinical trials were eventually adopted, this was not universally the case. Eight guidelines recommended that use of unproven agents should be considered on a case-by-case basis. Patient representatives expressed concern about the lack of engagement with them in CMG development and that these documents are not accessible to non-experts. Conclusion: The quality of most CMGs produced in coronaviridae outbreaks is poor and we have found no evidence of improvement over time, highlighting that current development frameworks must be improved. There is an need to strengthen the evidence base surrounding basic supportive care and develop methods to engage patients in CMG development from the beginning in outbreak settings. Systematic review registration- PROSPERO CRD42020167361

The SARS-CoV-2 pandemic has highlighted the disproportionate impact of infectious disease 87 outbreaks on vulnerable (e.g. the elderly and immunosuppressed) 2 and socioeconomically 88 disadvantaged groups in society. 3 Infectious diseases often present differently in these 89

populations and yet most CMGs produced early in the pandemic did not provide specific advice 90 for the management of these groups. 1 As knowledge about new diseases increases as time 91 elapses, the inclusivity, quality and usefulness of CMGs should also improve. Pandemics such 92 as COVID-19 are likely to occur with increasing frequency throughout the 21st Century and a 93 failure to improve the processes by which clinical practice learns and responds will ultimately 94 lead to unnecessary morbidity and mortality. 4 95 96

In this manuscript, we track the evolution of clinical management guidelines across three 97 coronaviridae pan/epidemics: SARS-CoV-1, MERS-CoV and SARS-CoV-2. We particularly 98 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 15, 2021. ; https://doi.org/10.1101/2021.01.12.21249654 doi: medRxiv preprint focus on whether the rigour of development of guidelines and inclusivity of vulnerable groups 99 has improved between these outbreaks and over the course of the COVID-19 pandemic. We 100 aim to identify the strengths and weaknesses of guidelines produced in these settings and to 101 evaluate whether lessons from previous outbreaks have been learnt. For a subset of guidelines 102 in the current SARS-CoV-2 pandemic we also examine how responsive these CMGs are in 103 incorporating new evidence from the latest clinical trials. In doing so we ask the bigger question 104 of how clinical management guidelines can be improved as health professionals continue to 105 manage large numbers of COVID-19 patients and for future pandemics. Search strategy 113 In a previous review, we found that most CMGs were not published in peer-reviewed journals 114 and rarely indexed in the electronic databases. 1 We therefore focussed our efforts on extensive 115 hand-searches of the grey literature using a combination of systematic Google and Google 116 Scholar searches and by specifically searching Ministry of Health, national public health agency 117 institutions, World Health Organisation (WHO), Centres for Disease Control and other infectious 118 disease society websites with pre-defined keywords (supplement). This was complemented by 119 utilising the International Severe Acute Respiratory and Emerging Infection Consortium 120 (ISARIC) 6 network to contact clinical networks in regions where limited numbers of CMGs where 121 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 15, 2021. Records identified from searches were independently screened, first by title and abstract, 134 followed by full text, by two reviewers. Individuals with knowledge of the language the CMG was 135 written in were used; where this was not possible translations were produced with Google 136

Translate. Any disagreements were resolved by a third reviewer. 137 Data extraction 138 We utilised a standardised form to extract data (supplement). Data was extracted by one 139 reviewer and checked by a second reviewer. 140 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 15, 2021. ; https://doi.org/10.1101/2021.01.12.21249654 doi: medRxiv preprint Quality assessment 141 The quality of each CMG was assessed using the Appraisal of Guidelines, Research and 142

Evaluation version II (AGREE-II). 8 The tool consists of 23 questions (scored on a 7-point scale, 143 from 1 (strongly disagree) to 7 (strongly agree) ) across six key domains (scope and purpose; 144 stakeholder involvement; rigour of development; clarity of presentation; applicability; editorial 145 independence). All CMGs were assessed using AGREE-II by two reviewers independently. 146

CMGs where there was significant discordance in the reviewers assessments were identified by 147 calculating Cohen's Kappa; a threshold of 0.4 was used to trigger further discussion between 148 reviewers to resolve major disagreements. We considered three measures of whether a CMG 149 was high quality: an overall weighted score ≥ 0.7 (threshold suggested by the AGREE-II 150 developers), weighted score ≥ 0.7 on domains 3 and 5 (rigour of development and applicability, 151 previously shown to be most predictive of overall score 9 ) and reviewers' overall assessment of 152 whether they would recommend use of the CMG. Weighted scores were calculated according to 153 the formula presented the AGREE-II manual 8 :

Responsiveness/Quality over time (subset analysis) 155 We tracked a subset of 11 COVID-19 CMGs (selected because they also featured in our earlier 156 rapid review 1 ) over time to assess their responsiveness to key results from randomised clinical 157 trials (RCTs) for six treatments (hydroxychloroquine, convalescent plasma, lopinavir-ritonavir, 158 remdesivir, dexamethasone and tocilizumab). For each CMG in this subset, we also compared 159 the AGREE-II scores to those given to earlier versions at the beginning of the pandemic in our 160 previous review. 161 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. CMGs were developed by government agencies and published on the websites as standalone 175 documents or acquired via the ISARIC 6 network. In contrast, SARS and MERS guidelines were 176 generally published in peer-reviewed journals. Although we attempted to ensure that there were 177 at least five national COVID-19 CMGs per continent, we found fewer guidelines produced in 178 Australasia (n=1), South America (n=3) and Africa (n=6), compared to North America (n=7), 179

Europe (n=12), and Asia (n=15). By the World Bank definition, 12 most guidelines were produced 180 in high (n=21) and upper middle (n=14), followed by lower middle (n=8) and low-income 181 countries (n=1). Three CMGs where produced by international agencies. 13-15 182 183 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. children, but older and other high-risk groups patients (e.g. immunosuppressed) were notable 223 omissions from many guidelines (Table 1 ). There were however some examples where this was 224 done well for example in the WHO CMG which includes specific sections relating to the care of 225 older people and pregnant women with COVID-19 as well as guidance on palliative care. 226 227 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 15, 2021. ;

These results demonstrate the need for a better framework for the development of CMGs in 317 outbreak settings. CMGs can still be useful and developed in a rigorous manner even when the 318 quality and quantity of evidence available is minimal. Dissemination of expert opinion may be 319 useful where there is no better option but should be clearly signposted as such and the rationale 320 for recommendations needs to be clearly and transparently presented. We suggest that at least 321 the initial methodology used to produce CMGs is subjected to a more transparent review 322 process and ideally that these reviews should also be published. This is particularly pertinent 323

given that the quality of CMGs did not appear to improve over time, is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 15, 2021. ; https://doi.org/10.1101/2021.01.12.21249654 doi: medRxiv preprint where guidelines either recommended an unproven agent for use in particular patient groups or 343 on a case-by-case basis. There is always a temptation for "compassionate use" of biologically 344 plausible agents for individual patients in extremis with no proven treatment option. 47 If however 345 all patients who were treated with steroids/hydroxychloroquine/remdesivir/convalescent plasma 346 had been randomised into trials from the beginning of the pandemic, we would have known 347 whether these agents are beneficial (or indeed harmful) much sooner and more patients could is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 15, 2021. ; https://doi.org/10.1101/2021.01.12.21249654 doi: medRxiv preprint response to epidemics and pandemics. This highlights a need for a CMG development 366 framework for the production of timely, evidence based, resource conscious, locally adaptable 367 and inclusive CMGs in response to emerging outbreaks. Vulnerable groups and in particular 368 the elderly continue to be disproportionately overlooked and the relevant specialities (e.g. 369 geriatrics) are underrepresented in CMG development groups. Given that COVID-19 has had 370 such a profound impact on so many people's lives and that such a vast quantity of public money 371 has been spent, involvement of patients and the public in outbreak preparedness and response, 372 including in CMG development is an area that needs to be urgently improved and must not be 373 The lead author affirms that the manuscript is an honest, accurate and transparent account of 406 the study being reported; no important aspects of the study have been omitted; any 407 discrepancies from the study as originally planned have been explained. 408 409 Acknowledgements 410

We would like to express our gratitude to the ISARIC network of Infectious disease 411 physicians/public health practitioners who were valuable in searching and providing clinical 412 management guidelines used in this review. Notably, the Ministry of Health Seychelles, 413

Christine Williams, Dr. Desmond Oppong at the Greater Accra Regional Hospital, Ghana and 414

Prof. Simon Anderson at the University of the West Indies. We thank our patient group for their 415 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 15, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 15, 2021. ; CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 15, 2021. ; https://doi.org/10.1101/2021.01.12.21249654 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 15, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 15, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 15, 2021. 

Scope, quality, and inclusivity of clinical guidelines produced 449 early in the covid-19 pandemic: rapid review

OpenSAFELY: factors associated with COVID-452 19-related hospital death in the linked electronic health records of 17 million adult NHS 453 patients

Disparities in the risk and outcomes of COVID-19, 2020. 455 4. Global Preparedness Monitoring Board. A World at Risk-Annual report on global 456 preparedness for health emergencies: World Health Organization

Preferred reporting items for systematic reviews 458 and meta-analyses: the PRISMA statement

International Severe Acute Respiratory and Emerging Infection Consortium. International 461 Severe Acute Respiratory and emerging Infection Consortium

Clinical guidelines we can trust. 464 National Academies Press

AGREE II: 466 advancing guideline development, reporting and evaluation in health care

Guideline appraisal with AGREE II: 469 Systematic review of the current evidence on how users handle the 2 overall 470 assessments

World Health Organisation

Surviving Sepsis Campaign: guidelines on the management of 486 critically ill adults with Coronavirus Disease 2019 (COVID-19)

World Health Organisation. Clinical management of severe acute respiratory infection when 489

Middle East respiratory syndrome coronavirus (MERS-CoV) infection is suspected

Antiviral treatment 497 guidelines for middle east respiratory syndrome

Infectious Diseases Society of America Guidelines on the Treatment and 503 Management of Patients with COVID-19 Version 1.0

Available from: www.idsociety.org/COVID19guidelines

Ministry of Health Family Welfare Bangladesh. National Guidelines on Clinical Management 506 of Coronavirus Disease 2019 (Covid-19) Verison

Clinical Management 510 Guidelines for COVID-19 Infections Version

588 Philippe; Zahar

Recommandations d'experts 590 portant sur la prise en charge en réanimation des patients en période d'épidémie à 591 SARS-CoV2 Version 2 du

Dexamethasone in Hospitalized Patients with Covid-595 19 -Preliminary Report

Effect of Hydrocortisone on 598 Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP 599 COVID-19 Corticosteroid Domain Randomized Clinical Trial

for the ACTT-1 study Group Members. Remdesivir for 605 the Treatment of Covid-19 -Final Report

SARS: systematic review of treatment effects

Coronavirus in the elderly: a late lockdown UK cohort

Provisional Standard Treatment Guidelines for Novel Coronavirus 616 Infection COVID -19 Guidelines for Ghana Version 1

COVID-19 Management Guidelines

Clinical management of suspected or 624 confirmed COVID-19 disease Version

Compassionate drug (mis)use during pandemics: lessons 630 for COVID-19 from

OrientaÇÕes Para Manejo De Pacientes Com

Fluxograma de Pacientes com Suspeita de Covid-19 nos Serviços 637 ambulatórios (Triagem e Consultas Externas) 2020

Ministerio de Salud Argentina. Recomendaciones Para El Abordaje Terapeutico Version

Australian Guideline for the Clinical Care of 647 People with COVID-19 2020

Ministry of Public Health. Directives Et Procedures Operationnelles Standards Pour La 650 Preparation Et La Reponse Au Covid-19 Au Cameroun

Infecciones por coronavirus -SARS

Infecciones por coronavirus -MERS

National Institute for Research in Reproductive Health Indian Council of Medical Research. 656 Guidance for Management of Pregnant Women in COVID-19 Pandemic 2020

Ministry of Health Family Welfare India. Revised Guidelines on Clinical Management of 664 COVID -19 2020

Gestione clinica dell ' infezione respiratoria acuta grave nei casi di 668 sospetta infezione da nuovo coronavirus ( nCoV )

Guideline for the management of Pregnancy 672 during the COVID-19 Pandemic 2020

Jamaica Ministry of Health and Wellness. Covid-19 Preparedness and Response Plan for 675 Outbreak Control Clinical Management of Severe Acute Respiratory Infection When 676 Novel Coronavirus Covid-19 Infection Is Suspected Version

_V3 2020

Orientações para a Abordagem e 687 Tratamento do doente Pediátrico na UCIP do Hospital Central Maputo com COVID-19

National Interim Guidelines for Clinical Management of 690 COVID-19 Version

National Committee for Management of Covid-United Arab Emirates. National Guidelines for 694 Clinical Management and Treatment of COVID-19 Version

Clinical management of persons admitted to hospital with 699 suspected COVID-19 infection Version

Fraga. 705 Recomendaciones para el Manejo No Invasivo e Invasivo de la Insuficiencia

Clinical management of severe acute respiratory infection 2020 710

The Korean Society of Pediatric Infection Diseases. COVID-19 Guidelines: Pediatric Care

Korean Society for Infectious Diseases Korean Society for Antibacterial Therapy Korean 716 Society for Pediatric Infections Korean Society for Tuberculosis

Hospital management of adults with severe acute respiratory 725 syndrome (SARS) if SARS re-emerges -updated

Chinese Medical Association CAoCM. Consensus of the management of severe acute 737 respiratory syndrome

Conduite à tenir pour 739 la prise en charge des personnes présentant un syndrome ou une

Management 744 guidelines for obstetric patients and neonates born to mothers with suspected or 745 probable severe acute respiratory syndrome (SARS). No. 225

Documento técnico Manejo clínico de pacientes con enfermedad por 752 el nuevo coronavirus (COVID-19) 2020

Manejo clínico del COVID-19: unidades de cuidados intensivos 2020 756

Medicamenteuze behandeling voor patiënten 759 met COVID-19 (infectie met SARS-CoV-2) 2020

Linee Guida Sulla Gestione Terapeutica e di 762 Supporto per Pazienti con Infezione da Coronavirus COVID-19 2020

Medicamenteuze behandelopties voor opgenomen patiënten met COVID

Documento técnico Manejo clínico del COVID-19: atención 769 hospitalaria 2020

British Thoracic Society and Scottish Intercollegiate Guidelines Network. SIGN158 British 773 guideline on the management of asthma. A national clinical guideline

Gruppo di Lavoro 777 COVID-19-SIMIT Lazio Comitato di Redazione 2020